valproic acid has been researched along with Pancreatic Neoplasms in 26 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
| Excerpt | Relevance | Reference |
|---|---|---|
| " We determined the anticancer effects of VPA combined with 5-FU in these cell lines." | 5.37 | Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines. ( Hanaoka, J; Ikemoto, T; Imura, S; Ishibashi, H; Iwahashi, S; Mori, H; Morine, Y; Ochir, TL; Shimada, M; Utsunomiya, T, 2011) |
| "To determine the role of gamma-aminobutyric acid (GABA) in islet tissue, sodium valproate (1600 mg/day) was administered for 6 days to 10 normal subjects and 1 patient with a somatostatinoma." | 5.06 | The effects of sodium valproate on plasma somatostatin and insulin in humans. ( Fujita, S; Ichii, S; Kusunoki, M; Nakai, T; Utsunomiya, J; Yamamura, T, 1988) |
| "Eight patients with low-grade NETs (carcinoid and pancreatic) were treated with 500 mg of oral VPA twice a day with dosing adjusted to maintain a goal VPA level between 50 and 100 μg/mL." | 2.76 | A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma. ( Chen, H; Eickhoff, J; Holen, KD; Jaskula-Sztul, R; Loconte, NK; Lubner, SJ; Mohammed, TA; Mulkerin, D; Schelman, WR, 2011) |
| " In conclusion, MDC-1112 should be further explored as a potential agent to be used in combination with GEM for treating PC." | 1.56 | Phospho-valproic acid (MDC-1112) reduces pancreatic cancer growth in patient-derived tumor xenografts and KPC mice: enhanced efficacy when combined with gemcitabine. ( Digiovanni, MG; Lacomb, JF; Luo, D; Mackenzie, GG; Rigas, B; Wei, R; Williams, JL, 2020) |
| "However, patients with pancreatic cancer benefit little from current existed therapies targeting the ErbB signaling." | 1.51 | Valproic acid exhibits anti-tumor activity selectively against EGFR/ErbB2/ErbB3-coexpressing pancreatic cancer via induction of ErbB family members-targeting microRNAs. ( Cai, J; Chen, J; Dong, H; Huang, L; Jia, R; Lei, Y; Lin, R; Lin, T; Peng, Y; Ren, Q; Tan, J; Wang, P; Wang, S; Xie, L; Yu, Z; Zhao, H; Zuo, W, 2019) |
| " Together our findings indicate that valproate which act as inhibitor of cell proliferation and inducer of apoptosis in human cancer MIAPaca2 cells when used in combination with nicotinamide makes it a potentially good candidate for new anticancer drug development." | 1.40 | Synergistic anticancer activity of valproate combined with nicotinamide enhances anti-proliferation response and apoptosis in MIAPaca2 cells. ( Ahmadian, S; Jafary, H; Soleimani, M, 2014) |
| "Valproic acid (VPA) acts as a specific inhibitor of class I HDACs and it use has been proven to be safe since a long time." | 1.40 | Valproic acid enhances the anti-tumor effect of pegylated interferon-α towards pancreatic cancer cell lines. ( Ikemoto, T; Imura, S; Iwahashi, S; Morine, Y; Shimada, M; Sugimoto, K; Utsunomiya, T, 2014) |
| "New agents are needed to treat pancreatic cancer, one of the most lethal human malignancies." | 1.39 | Targeting mitochondrial STAT3 with the novel phospho-valproic acid (MDC-1112) inhibits pancreatic cancer growth in mice. ( Alston, N; Constantinides, PP; Huang, L; Mackenzie, GG; Mattheolabakis, G; Ouyang, N; Rigas, B; Vrankova, K, 2013) |
| "PFTS inhibited the growth of human pancreatic cancer cells in culture in a concentration- and time-dependent manner." | 1.39 | A novel Ras inhibitor (MDC-1016) reduces human pancreatic tumor growth in mice. ( Alston, N; Bartels, LE; Mackenzie, GG; Ouyang, N; Papayannis, I; Rigas, B; Vrankova, K; Xie, G, 2013) |
| "The development of immunotherapy for pancreatic cancer has been hampered by difficulty in generating tumor-reactive lymphocytes from resected specimens and by a lack of appropriate target antigens expressed on tumor cells." | 1.38 | Targeting the MAGE A3 antigen in pancreatic cancer. ( Cogdill, AP; Cooper, ZA; Ferrone, CR; Fiedler, A; Frederick, DT; Garber, HR; Rosenberg, L; Thayer, SP; Wargo, JA; Warshaw, AL, 2012) |
| " We determined the anticancer effects of VPA combined with 5-FU in these cell lines." | 1.37 | Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines. ( Hanaoka, J; Ikemoto, T; Imura, S; Ishibashi, H; Iwahashi, S; Mori, H; Morine, Y; Ochir, TL; Shimada, M; Utsunomiya, T, 2011) |
| "Interestingly, treating pancreatic and colon cancer cells with valproic acid (VPA, 2-propylpentanoic acid), a known histone deacetylase (HDAC) inhibitor, leads to up-regulation of GRP78, an endoplasmic reticulum chaperone immunoglobulin-binding protein." | 1.36 | Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the alzheimer amyloid precursor protein. ( Bayer, TA; Iffland, L; Rossner, C; Schweyer, S; Tamboli, IY; Venkataramani, V; Walter, J; Wirths, O, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.85) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (11.54) | 29.6817 |
| 2010's | 20 (76.92) | 24.3611 |
| 2020's | 2 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Luo, D | 1 |
| Digiovanni, MG | 1 |
| Wei, R | 1 |
| Lacomb, JF | 1 |
| Williams, JL | 1 |
| Rigas, B | 4 |
| Mackenzie, GG | 4 |
| Giordano, F | 1 |
| Naimo, GD | 1 |
| Nigro, A | 1 |
| Romeo, F | 1 |
| Paolì, A | 1 |
| De Amicis, F | 1 |
| Vivacqua, A | 1 |
| Morelli, C | 1 |
| Mauro, L | 1 |
| Panno, ML | 1 |
| Dent, P | 1 |
| Booth, L | 1 |
| Poklepovic, A | 1 |
| Hoff, DV | 1 |
| Hancock, JF | 1 |
| Mattheolabakis, G | 2 |
| Wang, R | 1 |
| Lin, T | 1 |
| Ren, Q | 1 |
| Zuo, W | 1 |
| Jia, R | 1 |
| Xie, L | 1 |
| Lin, R | 1 |
| Zhao, H | 1 |
| Chen, J | 1 |
| Lei, Y | 1 |
| Wang, P | 1 |
| Dong, H | 1 |
| Huang, L | 2 |
| Cai, J | 1 |
| Peng, Y | 1 |
| Yu, Z | 1 |
| Tan, J | 1 |
| Wang, S | 1 |
| Bhat, J | 1 |
| Dubin, S | 1 |
| Dananberg, A | 1 |
| Quabius, ES | 1 |
| Fritsch, J | 1 |
| Dowds, CM | 1 |
| Saxena, A | 1 |
| Chitadze, G | 1 |
| Lettau, M | 1 |
| Kabelitz, D | 1 |
| Alston, N | 2 |
| Ouyang, N | 2 |
| Vrankova, K | 2 |
| Constantinides, PP | 1 |
| Li, J | 1 |
| Bonifati, S | 1 |
| Hristov, G | 1 |
| Marttila, T | 1 |
| Valmary-Degano, S | 1 |
| Stanzel, S | 1 |
| Schnölzer, M | 1 |
| Mougin, C | 1 |
| Aprahamian, M | 1 |
| Grekova, SP | 1 |
| Raykov, Z | 1 |
| Rommelaere, J | 1 |
| Marchini, A | 1 |
| Bartels, LE | 1 |
| Xie, G | 1 |
| Papayannis, I | 1 |
| Jafary, H | 1 |
| Ahmadian, S | 1 |
| Soleimani, M | 1 |
| Sugimoto, K | 2 |
| Shimada, M | 4 |
| Utsunomiya, T | 4 |
| Morine, Y | 4 |
| Imura, S | 4 |
| Ikemoto, T | 4 |
| Iwahashi, S | 4 |
| Arakawa, Y | 1 |
| Saito, Y | 2 |
| Ishikawa, D | 1 |
| Wang, Y | 1 |
| Kuramitsu, Y | 1 |
| Kitagawa, T | 1 |
| Tokuda, K | 1 |
| Baron, B | 1 |
| Akada, J | 1 |
| Nakamura, K | 1 |
| Sun, L | 1 |
| Qian, Q | 1 |
| Sun, G | 1 |
| Mackey, LV | 1 |
| Fuselier, JA | 1 |
| Coy, DH | 1 |
| Yu, CY | 1 |
| Gilardini Montani, MS | 1 |
| Granato, M | 1 |
| Santoni, C | 1 |
| Del Porto, P | 1 |
| Merendino, N | 1 |
| D'Orazi, G | 1 |
| Faggioni, A | 1 |
| Cirone, M | 1 |
| Jones, J | 1 |
| Bentas, W | 1 |
| Blaheta, RA | 1 |
| Makarevic, J | 1 |
| Hudak, L | 1 |
| Wedel, S | 1 |
| Probst, M | 1 |
| Jonas, D | 1 |
| Juengel, E | 1 |
| Fritsche, P | 2 |
| Seidler, B | 1 |
| Schüler, S | 2 |
| Schnieke, A | 1 |
| Göttlicher, M | 1 |
| Schmid, RM | 2 |
| Saur, D | 2 |
| Schneider, G | 2 |
| Venkataramani, V | 1 |
| Rossner, C | 1 |
| Iffland, L | 1 |
| Schweyer, S | 1 |
| Tamboli, IY | 1 |
| Walter, J | 1 |
| Wirths, O | 1 |
| Bayer, TA | 1 |
| Diersch, S | 1 |
| Arlt, A | 1 |
| Ishibashi, H | 1 |
| Ochir, TL | 1 |
| Hanaoka, J | 2 |
| Mori, H | 2 |
| Mohammed, TA | 1 |
| Holen, KD | 1 |
| Jaskula-Sztul, R | 1 |
| Mulkerin, D | 1 |
| Lubner, SJ | 1 |
| Schelman, WR | 1 |
| Eickhoff, J | 1 |
| Chen, H | 1 |
| Loconte, NK | 1 |
| Koga, H | 1 |
| Selvendiran, K | 1 |
| Sivakumar, R | 1 |
| Yoshida, T | 1 |
| Torimura, T | 1 |
| Ueno, T | 1 |
| Sata, M | 1 |
| Cogdill, AP | 1 |
| Frederick, DT | 1 |
| Cooper, ZA | 1 |
| Garber, HR | 1 |
| Ferrone, CR | 1 |
| Fiedler, A | 1 |
| Rosenberg, L | 1 |
| Thayer, SP | 1 |
| Warshaw, AL | 1 |
| Wargo, JA | 1 |
| Gibbs, JP | 1 |
| Adeyeye, MC | 1 |
| Yang, Z | 1 |
| Shen, DD | 1 |
| Kusunoki, M | 1 |
| Yamamura, T | 1 |
| Ichii, S | 1 |
| Fujita, S | 1 |
| Nakai, T | 1 |
| Utsunomiya, J | 1 |
3 trials available for valproic acid and Pancreatic Neoplasms
| Article | Year |
|---|---|
Effects of valproic acid in combination with S-1 on advanced pancreatobiliary tract cancers: clinical study phases I/II.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Drug C | 2014 |
A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Neuroendocrine; Dose-Response Relationshi | 2011 |
The effects of sodium valproate on plasma somatostatin and insulin in humans.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; C-Peptide; Female; gamma-Aminobutyric Acid; Humans; I | 1988 |
23 other studies available for valproic acid and Pancreatic Neoplasms
| Article | Year |
|---|---|
Phospho-valproic acid (MDC-1112) reduces pancreatic cancer growth in patient-derived tumor xenografts and KPC mice: enhanced efficacy when combined with gemcitabine.
Topics: Abnormalities, Multiple; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Li | 2020 |
Valproic Acid Addresses Neuroendocrine Differentiation of LNCaP Cells and Maintains Cell Survival.
Topics: Cell Differentiation; Cell Proliferation; Cell Survival; Humans; Neuroendocrine Tumors; Pancreatic N | 2019 |
Enhanced signaling via ERBB3/PI3K plays a compensatory survival role in pancreatic tumor cells exposed to [neratinib + valproate].
Topics: Cell Line, Tumor; Cell Survival; Humans; MAP Kinase Signaling System; Models, Biological; Pancreatic | 2020 |
Phospho-valproic acid inhibits pancreatic cancer growth in mice: enhanced efficacy by its formulation in poly-(L)-lactic acid-poly(ethylene glycol) nanoparticles.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Female; Humans; Lact | 2017 |
Valproic acid exhibits anti-tumor activity selectively against EGFR/ErbB2/ErbB3-coexpressing pancreatic cancer via induction of ErbB family members-targeting microRNAs.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Humans; Mice; Mice, Nude; MicroRNAs; Pancreatic Neopl | 2019 |
Histone Deacetylase Inhibitor Modulates NKG2D Receptor Expression and Memory Phenotype of Human Gamma/Delta T Cells Upon Interaction With Tumor Cells.
Topics: Acetylation; Cell Line, Tumor; GPI-Linked Proteins; Histocompatibility Antigens Class I; Histone Dea | 2019 |
Histone Deacetylase Inhibitor Modulates NKG2D Receptor Expression and Memory Phenotype of Human Gamma/Delta T Cells Upon Interaction With Tumor Cells.
Topics: Acetylation; Cell Line, Tumor; GPI-Linked Proteins; Histocompatibility Antigens Class I; Histone Dea | 2019 |
Histone Deacetylase Inhibitor Modulates NKG2D Receptor Expression and Memory Phenotype of Human Gamma/Delta T Cells Upon Interaction With Tumor Cells.
Topics: Acetylation; Cell Line, Tumor; GPI-Linked Proteins; Histocompatibility Antigens Class I; Histone Dea | 2019 |
Histone Deacetylase Inhibitor Modulates NKG2D Receptor Expression and Memory Phenotype of Human Gamma/Delta T Cells Upon Interaction With Tumor Cells.
Topics: Acetylation; Cell Line, Tumor; GPI-Linked Proteins; Histocompatibility Antigens Class I; Histone Dea | 2019 |
Targeting mitochondrial STAT3 with the novel phospho-valproic acid (MDC-1112) inhibits pancreatic cancer growth in mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cimetidine; Drug Synergism; Female; Hum | 2013 |
Synergistic combination of valproic acid and oncolytic parvovirus H-1PV as a potential therapy against cervical and pancreatic carcinomas.
Topics: Animals; Apoptosis; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Female; HeLa Cells; Histone | 2013 |
A novel Ras inhibitor (MDC-1016) reduces human pancreatic tumor growth in mice.
Topics: Animals; Antineoplastic Agents; Benzoates; Cell Line, Tumor; Drug Synergism; Female; Heterografts; H | 2013 |
Synergistic anticancer activity of valproate combined with nicotinamide enhances anti-proliferation response and apoptosis in MIAPaca2 cells.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Epigenesis, Genetic; Fl | 2014 |
Valproic acid enhances the anti-tumor effect of pegylated interferon-α towards pancreatic cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Caspases; Cell Line, Tumor; Drug Synergism; Histone | 2014 |
The Histone Deacetylase Inhibitor Valproic Acid Sensitizes Gemcitabine-Induced Cytotoxicity in Gemcitabine-Resistant Pancreatic Cancer Cells Possibly Through Inhibition of the DNA Repair Protein Gamma-H2AX.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; | 2015 |
Valproic acid induces NET cell growth arrest and enhances tumor suppression of the receptor-targeted peptide-drug conjugate via activating somatostatin receptor type II.
Topics: Animals; Apoptosis; Camptothecin; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Hist | 2016 |
Histone deacetylase inhibitors VPA and TSA induce apoptosis and autophagy in pancreatic cancer cells.
Topics: Apoptosis; Autophagy; Bortezomib; Cell Line, Tumor; Cell Survival; Drug Synergism; Extracellular Sig | 2017 |
Modulation of adhesion and growth of colon and pancreatic cancer cells by the histone deacetylase inhibitor valproic acid.
Topics: Cell Adhesion; Cell Proliferation; Cells, Cultured; Colonic Neoplasms; Down-Regulation; Enzyme Inhib | 2008 |
HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; DNA Damage; Drug | 2009 |
Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the alzheimer amyloid precursor protein.
Topics: Amyloid beta-Protein Precursor; Anticonvulsants; Cell Proliferation; Colonic Neoplasms; Down-Regulat | 2010 |
HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells.
Topics: Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Enzyme Inhibitors; Gen | 2010 |
Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell | 2011 |
Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-α on pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhib | 2011 |
PPARγ potentiates anticancer effects of gemcitabine on human pancreatic cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Deoxycytidine; | 2012 |
Targeting the MAGE A3 antigen in pancreatic cancer.
Topics: Adenocarcinoma; Antigens, Neoplasm; Azacitidine; Cell Line, Tumor; Chromatin Assembly and Disassembl | 2012 |
Valproic acid uptake by bovine brain microvessel endothelial cells: role of active efflux transport.
Topics: Adenocarcinoma; Animals; Biological Transport, Active; Brain; Cattle; Cells, Cultured; Cyclooxygenas | 2004 |